Exploring the Long Term Safety, Tolerability and Clinical Effect of Laquinimod

- Relapsing Remitting Multiple Sclerosis
- Terminated

Study Title: An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease

Teva Identifier: LAQ/5063OL | LAQ/5063 | 2005-004334-41

ClinicalTrials.gov Identifier: NCT00745615

Study Status: Terminated

Trial Condition(s): Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Laquinimod | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 18 Years to 50 Years

Trial Duration: December 7, 2005 - July 23, 2017

Phase: Phase 2

Study Type

Interventional